• 1
    De Boer-Dennert M, De Wit R, Schmitz PIM et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5-HT3 antagonists. Br J Cancer 1997;76:105561.
  • 2
    Thumas LJ. Über das Brechcentrum und über die Wirkung einiger pharmakologischer Mittel auf dasselbe [About the vomiting centre and about the effect of a pharmaceutical agent on the same]. Archieves für Patologische Anatomie 1891;123:4469.
  • 3
    Borison HL, Wang SC. Physiology and pharmacology of vomiting. Pharmacol Rev 1953;5:193230.
  • 4
    Herrstedt J, Hyttel J, Pedersen J. Interaction of the antiemetic metopimazine and anticancer agents with brain dopamine D2, 5-hydroxytryptamine3, histamine H1, muscarine cholinergic and α1-adrenergic receptors. Cancer Chemother Pharmacol 1993;33:536.
  • 5
    Hoyer D, Clarcke DE, Fozard JR et al. International Union of Pharmacology classification of receptors for 5-Hydroxytryptamine (serotonin). Pharmacol Rev 1994;46:157203.
  • 6
    Herrstedt J, Aapro MS, Smyth JF, Del Favero A. Corticosteroids, dopamine antagonists and other drugs. Support Care Cancer 1998;6:20414.
  • 7
    Morran C, Smith DC, Anderson DA, McArdle CS. Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomized trial of antiemetics. Br Med J 1979;19:13234.
  • 8
    Moertel CG, Reitemeier RJ. Controlled studies of metopimazine for the treatment of nausea and vomiting. J Clin Pharmacol 1973;13:2837.
  • 9
    Herrstedt J, Sigsgaard T, Handberg J et al. Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during cisplatinum-based chemotherapy in patients with cancer. J Clin Oncol 1997;15:16906.
  • 10
    Herrstedt J, Sigsgaard T, Boesgaard M, Jensen TP, Dombernowsky P. Ondansetron plus metopimazine compared to ondansetron alone i patients receiving moderately emetogenic chemotherapy. N Engl J Med 1993;328:107680.
  • 11
    Ioannidis PA, Hesketh PJ. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol 2000;18:340922.
  • 12
    Italian Group for Antiemetic Research. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin acute emesis. J Clin Oncol 1998;16:293748.
  • 13
    Italian Group for Antiemetic Research. Randomized, double-blind, dose-finding study of dexamethasone in the prevention of acute emesis induced by anthracyclines, carboplatin and cyclophosphamide. J Clin Oncol 2004;22:7259.
  • 14
    Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol 2007;18:23340.
  • 15
    Walsh D, Nelson KA, Mahmoud FA. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 2003; 11:13743.
  • 16
    Gralla RJ, Itri L, Pisko S et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 1981;305:9059.
  • 17
    Miner WD, Sanger GJ. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 1986;88:4979.
  • 18
    Bonneterre J, Chevallier B, Metz R et al. A randomized, double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil and doxorubicin or epirubicin chemotherapy. J Clin Oncol 1990;8:10639.
  • 19
    Kaasa S, Kvaloy S, Dicato MA et al. A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. Eur J Cancer 1990;26:3114.
  • 20
    Marschner NW, Adler M, Nagel GA, Christmann D, Fennzl E, Upadhyaya B. Double-blind, randomized trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. Eur J Cancer 1991;27:113740.
  • 21
    Jones AL, Hill AS, Soukop M et al. Comparison of ondansetron and dexamethasone in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 1991;338:4837.
  • 22
    De Mulder PHM, Seynaeve C, Vermorken JB et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 1990;113:83440.
  • 23
    Marty M, Pouillart P, Scholl S et al. Comparison of the 5-hydroxytryptamine (serotonin), antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990;322:81621.
  • 24
    Warr D, Willan A, Fine S et al. Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis. J Natl Cancer Inst 1991;83:116973.
  • 25
    Warr DG, Wilan A, Venner P et al. A randomized, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. Eur J Cancer 1993;29A:336.
  • 26
    Italian Group for Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone in the prevention of cisplatin-induced acute emesis. Ann Oncol 1995;6:80510.
  • 27
    Gralla RJ, Navari RM, Hesketh PJ et al. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol 1998;16:156873.
  • 28
    Perez EA, Hesketh PJ, Sandbach J et al. Comparison of single-dose, oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. A multicenter, double-blind, randomized parallel study. J Clin Oncol 1998;16:75460.
  • 29
    Eisenberg P, Figueroa-Vadillo J, Zamora R et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist. Cancer 2003;98:247382.
  • 30
    Gralla RJ, Lichinitser M, Van der Vegt S et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:15707.
  • 31
    Aapro MS, Grunberg SM, Manikhas GM et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006;17:14419.
  • 32
    von Euler VS, Gaddum JH. An unidentified depressor substance in certain tissue extracts. J Physiol (Lond) 1931;72:57783.
  • 33
    Chang M, Leeman SE. Isolation of sialogogic peptide from bovine hypothalamic tissue and its characterization as substance P. J Biol Chem 1970;245:478490.
  • 34
    Kris MG, Radford JE, Pizzo BA, Inabinet R, Hesketh A, Hesketh PJ. Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin. J Natl Cancer Inst 1987; 89:81718.
  • 35
    Cocquyt V, Van Belle S, Reinhardt RR et al. Comparison of L-758298, a prodrug for the selective neurokinin-1 antagonist, L-754030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 2001;37:83542.
  • 36
    Navari RM, Reinhardt RR, Gralla RJ et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. N Engl J Med 1999;340:1905.
  • 37
    Hesketh PJ, Grunberg SM, Gralla RJ et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin – The aprepitant 052 study group. J Clin Oncol 2003;21:41129.
  • 38
    Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97:30908.
  • 39
    Schmoll HJ, Aapro MS, Poli-Bigelli S et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 2006;17:41129.
  • 40
    Warr DG, Hesketh PJ, Gralla RJ et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:282230.
  • 41
    de Witt R, Herrstedt J, Rapoport B et al. The oral NK1 antagonist aprepitant given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of 2 randomized, placebo-controlled phase III trials. Eur J Cancer 2004;40:40310.
  • 42
    Herrstedt J, Muss HB, Warr DG et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately emetogenic chemotherapy. Cancer 2005;104:154855.
  • 43
    Blower P, De Witt R, Goodin S, Aapro M. Drug-drug interactions in oncology: why are they important and can they be minimized? Clin Rev Oncol Hematol 2005;55:11742.
  • 44
    Herrstedt J. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting. Expert Opin Drug Saf 2004;3:23148.
  • 45
    Nygren P, Hande K, Petty KJ et al. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol 2005;55:60916.
  • 46 Merck background information package for the panel members of the advisory committee.
  • 47
    Blum RA, Majumdar A, McCrea J et al. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther 2003;25:140719.
  • 48
    Antiemetic Subcommittee of MASCC. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006;17:208.
  • 49
    Kris MG, Hesketh PJ, Somerfield MR et al. ASCO guidelines for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:293247.
  • 50
    Herrstedt J. Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol 2007;18:ii83ii85.
  • 51
    Navari RM, Einhorn LH, Giovannini M et al. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group Study. Support Care Cancer 2005;13:52934.
  • 52
    Rudd JA, Ngan MP, Wai MK et al. Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin. Neurosci Lett 2006;392:7983.
  • 53
    Tremblay PB, Kaizer R, Sezer O et al. Variations in the 5-HT3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol 2003;21:214755.
  • 54
    Grunberg SM, Osoba D, Hesketh PJ et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity – an update. Support Care Cancer 2005;13:804.